Company

AstraZeneca

Pharmaceutical intelligence for AstraZeneca with 76 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 26
Catalysts: 50
Assets: 28

Recent signals(26)

ClinicalJune 19, 2026

Pentoxifylline and α-Tocopherol Study for RILI in Stage III NSCLC Patients

A clinical trial is investigating the efficacy of Pentoxifylline and α-Tocopherol in preventing radiation-induced lung injury in stage III NSCLC patients.

CompetitiveJune 19, 2026

AstraZeneca Leads Study on DLBCL Treatment Patterns in MEA Region

AstraZeneca is sponsoring a multicenter observational study to analyze treatment patterns and access to novel therapies for DLBCL patients in the MEA region.

RegulatoryJune 18, 2026

FDA Acceptance of NDA for Capivasertib by AstraZeneca

The FDA has accepted the NDA for Capivasertib, indicating progress in its regulatory review.

ClinicalJune 18, 2026

Phase II Trial of Olaparib and Durvalumab Combinations in Recurrent Endometrial Cancer

A phase II trial is evaluating the efficacy of combinations of olaparib, durvalumab, cediranib, and capivasertib in recurrent or refractory endometrial cancer.

ClinicalJune 18, 2026

Phase II Trial of Selumetinib and Olaparib in RAS Pathway Mutant Ovarian and Endometrial Cancers

A phase II trial is comparing the efficacy of selumetinib plus olaparib versus selumetinib alone in patients with RAS pathway mutant recurrent or persistent ovarian and endometrial cancers.

RegulatoryJune 18, 2026

FDA Accepts Application for BAXFENDY (BAXDROSTAT) from AstraZeneca

The FDA has accepted the New Drug Application for BAXFENDY (BAXDROSTAT) from AstraZeneca.

ClinicalJune 18, 2026

EVOLVE Study to Assess Real-World Effectiveness of Tezepelumab in Severe Asthma in Greece

The EVOLVE study will evaluate the real-world effectiveness of tezepelumab in uncontrolled severe asthma over two years in Greece.

ClinicalJune 17, 2026

Study on Durvalumab, Bevacizumab, and TACE for Advanced Hepatocellular Carcinoma

A clinical trial is evaluating the combination of durvalumab, bevacizumab, and TACE for advanced HCC, focusing on 6-month progression-free survival.

ClinicalJune 17, 2026

Phase III Trial of MEDI5752 in Unresectable Pleural Mesothelioma Launched

A phase III trial is underway to evaluate the efficacy and safety of MEDI5752 in combination with standard chemotherapy in patients with unresectable pleural mesothelioma.

ClinicalJune 17, 2026

Phase III Study of Durvalumab + Domvanalimab in Stage III Unresectable NSCLC Initiated

A Phase III trial is underway to evaluate the combination of durvalumab and domvanalimab in patients with unresectable NSCLC.

ClinicalJune 17, 2026

Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer

A phase III trial is comparing osimertinib alone versus its combination with bevacizumab in patients with EGFR-mutant non-small cell lung cancer.

ClinicalJune 17, 2026

Phase III Trial of Durvalumab with Chemotherapy in Stage II-III Breast Cancer

A phase III trial is evaluating the addition of durvalumab to standard chemotherapy in patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

ClinicalJune 17, 2026

Phase III Trial Evaluates Hormone Therapy and Chemotherapy in Invasive Breast Cancer

A randomized phase III trial is assessing the efficacy of tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy in invasive breast cancer.

RegulatoryJune 16, 2026

FDA ODAC Vote Against Camizestrant for HR-Positive Breast Cancer Raises Concerns

The FDA's ODAC did not reach a majority vote in favor of camizestrant's benefit-risk profile for advanced HR-positive breast cancer.

StrategyJune 16, 2026

AstraZeneca Reports Strong Q1 2026 Revenue Growth and Positive NME Readouts

AstraZeneca reported a 13% increase in total revenue for Q1 2026, driven by strong product sales and positive readouts from new molecular entities (NMEs).

RegulatoryJune 16, 2026

Saphnelo Self-Administration Approved in the US for SLE Treatment

AstraZeneca's Saphnelo has received FDA approval for self-administration via a new autoinjector, enhancing patient convenience.

RegulatoryJune 16, 2026

FDA Extends Decision Date for AstraZeneca's Camizestrant in HR-positive Breast Cancer

The FDA has extended the PDUFA date for camizestrant to allow for additional data review related to its NDA.

RegulatoryJune 16, 2026

Truqap approved in US for PTEN-deficient metastatic prostate cancer

Truqap, a first-in-class AKT inhibitor, has been approved in the US for treating PTEN-deficient metastatic hormone-sensitive prostate cancer.

RegulatoryJune 16, 2026

Imfinzi Gains US Approval for Early Bladder Cancer with BCG Combination

Imfinzi has been approved in the US as the first immunotherapy combination for BCG-naïve, high-risk non-muscle-invasive bladder cancer, showing a 32% reduction in disease recurrence, progression, or death.

RegulatoryJune 16, 2026

Enhertu Gains FDA Approval for Two New HER2+ Early Breast Cancer Indications

Enhertu has received FDA approval for two new indications in HER2-positive early breast cancer, both before and after surgery.

RegulatoryJune 16, 2026

FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer

The FDA ODAC has recommended Truqap in combination with abiraterone and ADT for PTEN-deficient metastatic hormone-sensitive prostate cancer.

RegulatoryJune 16, 2026

Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer

Datroway is approved in the US as the first TROP2-directed antibody drug conjugate for 1st-line treatment of metastatic triple-negative breast cancer.

ClinicalJune 16, 2026

Imfinzi + EV shows significant survival benefits in muscle-invasive bladder cancer

The Phase III VOLGA trial demonstrated that perioperative Imfinzi plus neoadjuvant EV significantly improves event-free survival and shows a favorable trend in overall survival for muscle-invasive bladder cancer.

RegulatoryJune 16, 2026

Camizestrant Recommended for 1st-Line ER-Positive Breast Cancer in EU

Camizestrant, in combination with CDK4/6 inhibitor, has been recommended for approval in the EU for 1st-line advanced ER-positive breast cancer based on SERENA-6 trial results.

ClinicalJune 16, 2026

Tozorakimab Shows Positive Phase III Results in COPD, Reducing Exacerbations

Tozorakimab met its primary endpoint in the Phase III MIRANDA trial, showing significant reduction in COPD exacerbations.

ClinicalJune 16, 2026

Ultomiris meets primary endpoint in Phase III trial for IgAN

Ultomiris showed a statistically significant reduction of proteinuria in adults with immunoglobulin A nephropathy in the Phase III I CAN trial.

Upcoming catalysts(1)

Phase III Readout

AstraZeneca — Imfinzi

Positive data would strengthen AZ IO portfolio against Merck dominance in thoracic oncology.

October 12, 2026 · Phase III

Regulatory activity(11)

RegulatoryJune 18, 2026

FDA Acceptance of NDA for Capivasertib by AstraZeneca

The FDA has accepted the NDA for Capivasertib, indicating progress in its regulatory review.

RegulatoryJune 18, 2026

FDA Accepts Application for BAXFENDY (BAXDROSTAT) from AstraZeneca

The FDA has accepted the New Drug Application for BAXFENDY (BAXDROSTAT) from AstraZeneca.

RegulatoryJune 16, 2026

FDA ODAC Vote Against Camizestrant for HR-Positive Breast Cancer Raises Concerns

The FDA's ODAC did not reach a majority vote in favor of camizestrant's benefit-risk profile for advanced HR-positive breast cancer.

RegulatoryJune 16, 2026

Saphnelo Self-Administration Approved in the US for SLE Treatment

AstraZeneca's Saphnelo has received FDA approval for self-administration via a new autoinjector, enhancing patient convenience.

RegulatoryJune 16, 2026

FDA Extends Decision Date for AstraZeneca's Camizestrant in HR-positive Breast Cancer

The FDA has extended the PDUFA date for camizestrant to allow for additional data review related to its NDA.

RegulatoryJune 16, 2026

Truqap approved in US for PTEN-deficient metastatic prostate cancer

Truqap, a first-in-class AKT inhibitor, has been approved in the US for treating PTEN-deficient metastatic hormone-sensitive prostate cancer.

RegulatoryJune 16, 2026

Imfinzi Gains US Approval for Early Bladder Cancer with BCG Combination

RegulatoryJune 16, 2026

Enhertu Gains FDA Approval for Two New HER2+ Early Breast Cancer Indications

Enhertu has received FDA approval for two new indications in HER2-positive early breast cancer, both before and after surgery.

RegulatoryJune 16, 2026

FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer

The FDA ODAC has recommended Truqap in combination with abiraterone and ADT for PTEN-deficient metastatic hormone-sensitive prostate cancer.

RegulatoryJune 16, 2026

Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer

Datroway is approved in the US as the first TROP2-directed antibody drug conjugate for 1st-line treatment of metastatic triple-negative breast cancer.

RegulatoryJune 16, 2026

Camizestrant Recommended for 1st-Line ER-Positive Breast Cancer in EU

Camizestrant, in combination with CDK4/6 inhibitor, has been recommended for approval in the EU for 1st-line advanced ER-positive breast cancer based on SERENA-6 trial results.

Clinical activity(13)

ClinicalJune 19, 2026

Pentoxifylline and α-Tocopherol Study for RILI in Stage III NSCLC Patients

A clinical trial is investigating the efficacy of Pentoxifylline and α-Tocopherol in preventing radiation-induced lung injury in stage III NSCLC patients.

ClinicalJune 18, 2026

Phase II Trial of Olaparib and Durvalumab Combinations in Recurrent Endometrial Cancer

A phase II trial is evaluating the efficacy of combinations of olaparib, durvalumab, cediranib, and capivasertib in recurrent or refractory endometrial cancer.

ClinicalJune 18, 2026

Phase II Trial of Selumetinib and Olaparib in RAS Pathway Mutant Ovarian and Endometrial Cancers

A phase II trial is comparing the efficacy of selumetinib plus olaparib versus selumetinib alone in patients with RAS pathway mutant recurrent or persistent ovarian and endometrial cancers.

ClinicalJune 18, 2026

EVOLVE Study to Assess Real-World Effectiveness of Tezepelumab in Severe Asthma in Greece

The EVOLVE study will evaluate the real-world effectiveness of tezepelumab in uncontrolled severe asthma over two years in Greece.

ClinicalJune 17, 2026

Study on Durvalumab, Bevacizumab, and TACE for Advanced Hepatocellular Carcinoma

A clinical trial is evaluating the combination of durvalumab, bevacizumab, and TACE for advanced HCC, focusing on 6-month progression-free survival.

ClinicalJune 17, 2026

Phase III Trial of MEDI5752 in Unresectable Pleural Mesothelioma Launched

A phase III trial is underway to evaluate the efficacy and safety of MEDI5752 in combination with standard chemotherapy in patients with unresectable pleural mesothelioma.

ClinicalJune 17, 2026

Phase III Study of Durvalumab + Domvanalimab in Stage III Unresectable NSCLC Initiated

A Phase III trial is underway to evaluate the combination of durvalumab and domvanalimab in patients with unresectable NSCLC.

ClinicalJune 17, 2026

Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer

A phase III trial is comparing osimertinib alone versus its combination with bevacizumab in patients with EGFR-mutant non-small cell lung cancer.

ClinicalJune 17, 2026

Phase III Trial of Durvalumab with Chemotherapy in Stage II-III Breast Cancer

A phase III trial is evaluating the addition of durvalumab to standard chemotherapy in patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

ClinicalJune 17, 2026

Phase III Trial Evaluates Hormone Therapy and Chemotherapy in Invasive Breast Cancer

A randomized phase III trial is assessing the efficacy of tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy in invasive breast cancer.

ClinicalJune 16, 2026

Imfinzi + EV shows significant survival benefits in muscle-invasive bladder cancer

ClinicalJune 16, 2026

Tozorakimab Shows Positive Phase III Results in COPD, Reducing Exacerbations

Tozorakimab met its primary endpoint in the Phase III MIRANDA trial, showing significant reduction in COPD exacerbations.

ClinicalJune 16, 2026

Ultomiris meets primary endpoint in Phase III trial for IgAN

Ultomiris showed a statistically significant reduction of proteinuria in adults with immunoglobulin A nephropathy in the Phase III I CAN trial.

Competitive activity(1)

CompetitiveJune 19, 2026

AstraZeneca Leads Study on DLBCL Treatment Patterns in MEA Region

AstraZeneca is sponsoring a multicenter observational study to analyze treatment patterns and access to novel therapies for DLBCL patients in the MEA region.